{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:56:06Z","timestamp":1788904566179,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>In patients with clinically lymph node-negative (cN0) breast cancer, performing sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) has been preferentially embraced in comparison to before NACT. However, survival outcomes associated with both strategies remain understudied. We aimed to compare the axillary lymphadenectomy (ALND) rate, disease-free survival (DFS), and overall survival (OS), between two strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 310 patients in a retrospective observational study. SNLB was performed before NACT from December 2006 to April 2014 (107 cases) and after NACT from May 2014 to May 2020 (203 patients). An inverse probability of treatment weighting (IPTW) method was applied to homogenize both groups. Hazard ratios (HR) and odd ratios (OR) are reported with 95% confidence intervals (95%CI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The lymphadenectomy rate was 29.9% before NACT and 7.4% after NACT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with an OR of 5.35 95%CI (2.7\u201310.4); <jats:italic>p<\/jats:italic>\u2009=\u2009.002. After 4\u00a0years of follow-up, SLNB after NACT was associated with lower risk for DFS, HR 0.42 95%CI (0.17\u20131.06); <jats:italic>p<\/jats:italic>\u2009=\u20090.066 and better OS, HR 0.21 CI 95% (0.07\u20130.67); <jats:italic>p<\/jats:italic>\u2009=\u20090.009 than SLNB before NACT. After multivariate analysis, independent adverse prognostic factors for OS included SLNB before NACT, HR 3.095 95%CI (2.323\u20134.123), clinical nonresponse to NACT, HR 1.702 95% CI (1.012\u20132.861), and small tumors (cT1) with high proliferation index, HR 1.889 95% (1.195\u20132.985).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Performing SLNB before NACT results in more ALND and has no benefit for patient survival. These findings support discontinuing the practice of SLNB before NACT in patients with cN0 breast cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-024-07274-1","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:01:53Z","timestamp":1713438113000},"page":"131-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival\u2014a propensity score cohort study"],"prefix":"10.1007","volume":"206","author":[{"given":"Sergi","family":"Fernandez-Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Falo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Pla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ortega-Exposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bosch-Schips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Bajen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonz\u00e1lez-Viguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Pe\u00f1afiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Stradella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Pernas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Garcia-Tejedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"7274_CR1","doi-asserted-by":"crossref","unstructured":"Jackisch C, Harbeck N, Huober J et al. 14th St Gallen International Breast Cancer Conference 2015: evidence, controversies, consensus - primary therapy of early breast cancer: opinions expressed by German Experts. Breast Care. 2015;10(211\u20139).","DOI":"10.1159\/000433590"},{"issue":"10","key":"7274_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927\u2013933","journal-title":"Lancet Oncol"},{"issue":"6","key":"7274_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-n- ode biopsy with routine axillary dissection in breast cancer. N Engl J Med 349(6):546\u2013553","journal-title":"N Engl J Med"},{"issue":"Supplement 5","key":"7274_CR4","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E et al (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Supplement 5):v8-30","journal-title":"Ann Oncol"},{"issue":"1","key":"7274_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clbc.2017.08.014","volume":"18","author":"S Fernandez-Gonzalez","year":"2018","unstructured":"Fernandez-Gonzalez S, Falo C, Pla MJ, Pernas S, Bajen M, Soler T et al (2018) The shift from sentinel lymph node biopsy performed either before or after neoadjuvant systemic therapy in the clinical negative nodes of breast cancer patients. Results, and the advantages and disadvantages of both procedures. Clin Breast Cancer 18(1):71\u201377","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"7274_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1245\/ASO.2006.07.025","volume":"13","author":"MC van Rijk","year":"2006","unstructured":"van Rijk MC, Nieweg OE, Rutgers EJ et al (2006) Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. Ann Surg Oncol 13(4):475\u2013479","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"7274_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/archsurg.143.7.692","volume":"143","author":"BJ Grube","year":"2008","unstructured":"Grube BJ, Christy CJ, Black D et al (2008) Breast sentinel lymph node dissection before preoperative chemotherapy. Arch Surg 143(7):692\u2013699","journal-title":"Arch Surg"},{"key":"7274_CR8","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.ejca.2009.08.001","volume":"45","author":"CH van Deurzen","year":"2009","unstructured":"van Deurzen CH, Vriens BE, Tjan-Heijnen VC et al (2009) Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer 45:3124\u20133130","journal-title":"Eur J Cancer"},{"key":"7274_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.acra.2009.01.026","volume":"16","author":"AM Kelly","year":"2009","unstructured":"Kelly AM, Dwamena B, Cronin PCR (2009) Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta-analysis. Acad Radiol 16:551\u2013563","journal-title":"Acad Radiol"},{"issue":"24","key":"7274_CR10","first-page":"18","volume":"25","author":"A Shirzadi","year":"2019","unstructured":"Shirzadi A, Habibollah Mahmoodzadeh MQ (2019) Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups Initially node negative and node positive converted to node negative \u2013 A systemic review and meta-analysis. J Res Med Sci 25(24):18","journal-title":"J Res Med Sci"},{"key":"7274_CR11","unstructured":"Network NCC. Breast cancer. Version 4.2020. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"10","key":"7274_CR12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM et al (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32(10):1216\u20131235","journal-title":"Ann Oncol"},{"key":"7274_CR13","unstructured":"Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al. Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023; ep 6:S0923\u20137534(23)00835\u20139."},{"issue":"1","key":"7274_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-022-06522-6","volume":"193","author":"S Gandhi","year":"2022","unstructured":"Gandhi S, Brackstone M, Hong NJL, Grenier D, Donovan E, Lu F-I et al (2022) A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat 193(1):1\u201320","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"7274_CR15","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1055\/a-1499-8431","volume":"81","author":"M Friedrich","year":"2021","unstructured":"Friedrich M, K\u00fchn T, Wolfgang Janni VM et al (2021) AGO recommendations for the surgical therapy of the axilla after neoadjuvant chemotherapy: 2021 update. Geburtshilfe Frauenheilkd 81(10):1112\u20131120","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"16","key":"7274_CR16","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-06-2512","volume":"13","author":"M Tsujimoto","year":"2007","unstructured":"Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F et al (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13(16):4807\u20134816","journal-title":"Clin Cancer Res"},{"issue":"22","key":"7274_CR17","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147\u20132159","journal-title":"N Engl J Med"},{"issue":"5","key":"7274_CR18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1148\/rg.335125214","volume":"33","author":"T Tirkes","year":"2013","unstructured":"Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik FSK (2013) Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 33(5):1323\u20131341","journal-title":"Radiographics"},{"issue":"21","key":"7274_CR19","first-page":"5222","volume":"16","author":"TO Nielsen","year":"2010","unstructured":"Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Cancer Res 16(21):5222\u20135232","journal-title":"Cancer Res"},{"issue":"9","key":"7274_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"Goldhirsch a, Winer EP, Coates a S,","year":"2013","unstructured":"Goldhirsch a, Winer EP, Coates a S, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206\u20132223","journal-title":"Ann Oncol"},{"issue":"1","key":"7274_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/BD-210043","volume":"41","author":"S Salinas-Huertas","year":"2022","unstructured":"Salinas-Huertas S, Luzardo-Gonz\u00e1lez A, V\u00e1zquez-Gallego S, Pernas S, Falo C, Pla MJ et al (2022) Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsy. Breast Dis 41(1):97\u2013108","journal-title":"Breast Dis"},{"key":"7274_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004561.pub3","author":"N Bromham","year":"2017","unstructured":"Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW (2017) Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD004561.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"7274_CR23","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1007\/s12094-022-02824-9","volume":"24","author":"JC V\u00e1zquez","year":"2022","unstructured":"V\u00e1zquez JC, Pi\u00f1ero A, de Castro FJ, Lluch A, Mart\u00edn M, Barnadas A et al (2022) The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview. Clin Transl Oncol 24(9):1744\u20131754","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"7274_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12282-021-01280-7","volume":"29","author":"L Zarifmahmoudi","year":"2022","unstructured":"Zarifmahmoudi L, Aghaee A, Treglia G, Sadeghi R (2022) Sentinel lymph node mapping in breast cancer patients following neoadjuvant chemotherapy: systematic review and meta-analysis about head to head comparison of cN0 and cN + patients. Breast Cancer 29(1):50\u201364","journal-title":"Breast Cancer"},{"issue":"5","key":"7274_CR25","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1245\/s10434-021-11297-z","volume":"29","author":"SQ Lin","year":"2022","unstructured":"Lin SQ, Vo NP, Yen YC, Tam KW (2022) Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data. Ann Surg Oncol 29(5):3038\u20133049","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"7274_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0162605","volume":"11","author":"C Geng","year":"2016","unstructured":"Geng C, Chen X, Pan X, Li J (2016) The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: A systematic review and meta-analysis. PLoS ONE 11(9):1\u201316","journal-title":"PLoS ONE"},{"issue":"5","key":"7274_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ejso.2013.02.011","volume":"39","author":"Fontein DBY, Van De Water W, Mieog JSD, Liefers GJ, Van De Velde CJH","year":"2013","unstructured":"Fontein DBY, Van De Water W, Mieog JSD, Liefers GJ, Van De Velde CJH (2013) Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy-Recommendations for clinical guidance. Eur J Surg Oncol 39(5):417\u2013424","journal-title":"Eur J Surg Oncol"},{"key":"7274_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ejso.2013.05.002","volume":"39","author":"J Navarro-Cecilia","year":"2013","unstructured":"Navarro-Cecilia J, Due\u00f1as-Rodr\u00edguez B, Luque-L\u00f3pez C et al (2013) Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy. Eur J Surg Oncol 39:873\u2013879","journal-title":"Eur J Surg Oncol"},{"key":"7274_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","volume":"250","author":"KK Hunt","year":"2009","unstructured":"Hunt KK, Yi M, Mittendorf EA et al (2009) Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 250:558\u2013566","journal-title":"Ann Surg"},{"issue":"2","key":"7274_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF et al (2019) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 173(2):343\u2013352","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"7274_CR31","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K et al (2019) Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 26(11):3502\u20133509","journal-title":"Ann Surg Oncol"},{"key":"7274_CR32","doi-asserted-by":"publisher","first-page":"100496","DOI":"10.1016\/j.conctc.2019.100496","volume":"17","author":"C Tinterri","year":"2019","unstructured":"Tinterri C, Canavese G, Paolo Bruzzi BD (2019) NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy. Contemp Clin Trials Commun. 17:100496","journal-title":"Contemp Clin Trials Commun."},{"key":"7274_CR33","unstructured":"V. Galimberti, B.F. Cole, G. Viale, P. Veronesi, E. Vicini, M. Intra GM, Massaru et al. International Breast Cancer Study Group Trial 23\u201301. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinelnode micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial,. Lancet Oncol 1. 9((10)):1385\u20131393,."},{"key":"7274_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel node micrometastasis (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol 14:297\u2013305","journal-title":"Lancet Oncol"},{"key":"7274_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1184021","author":"A Garcia-Tejedor","year":"2023","unstructured":"Garcia-Tejedor A, Ortega-Exposito C, Salinas S, Luzardo-Gonz\u00e1lez A, Falo C, Martinez-P\u00e9rez E, H\u00e9ctor P\u00e9rez-Montero M, Soler-Mons\u00f3 T, Bajen M-T, Benitez A, Ortega R, Petit A, Guma A, Campos M, Maria ML (2023) Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1184021","journal-title":"Front Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07274-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:13:08Z","timestamp":1718604788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07274-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7274"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07274-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Fernandez-Gonzalez, C. Falo, M.J Pla, M. Campos, C. Ortega, R. Ortega, M. Vicente, A. Petit, J. Bosch, M.T Bajen, G. Reyes, E. Mart\u00ednez, J. Gonzalez, J. Ponce and A. Garcia-Tejedor do not have any financial\/non-financial interest.\nA.Stradella declares:\n\u2022Speaker\u2019s bureau: Daiichi, Novartis, Astra Zeneca\n\u2022Travel, accommodations or expenses paid: Eisai, Novartis, and Pfizer\n\u2022Advisory role: Astra Zeneca, Boehringer Ingelheim, Novartis, Seagen and Gilead\n\u2022Non-financial disclosure: member of GEICAM's Executive Board\nS. Pernas declares:\n\u2022Advisor\/Consultant: AstraZeneca-Daiichi; Gebro; Pfizer; Pierre-Fabre; SeaGen\n\u2022Speaker honoraria: AstraZeneca-Daiichi; Eisai; Gilead; Lilly; Novartis; Roche;\n\u2022Travel grants from AstraZeneca-Daiichi; Pfizer; Gilead; Roche\n\u2022Non-financial disclosure: member of SOLTI's Executive Board and Scientific Committee","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors declare that they have no financial interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee from our hospital (247\/06).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study to be treated and analyzed in our institution.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}